课题基金 / 基金详情

Nanoparticle properties and alveolar epithelial barrier/transport functions

Nanoparticle properties and alveolar epithelial barrier/transport functions
纳米颗粒特性和肺泡上皮屏障/运输功能
批准号:
7735746
负责人:
EDWARD DAVID CRANDALL
金额:
$36.68万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-15 至 2014-03-31

项目摘要

项目成果

EDWARD DAVID CRANDALL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):吸入超细(纳米)颗粒与心血管、肺和血液学不良反应、颗粒在血管和终末器官中的定位以及易感人群发病率和死亡率增加相关。由于颗粒被吸入,它们进入体循环的最可能途径是穿过肺的肺泡上皮。虽然由于纳米技术的科学和应用的扩展,纳米颗粒的利用预计将显着增加,纳米颗粒损伤和/或被运送到/穿过肺泡上皮的机制还不清楚。基于我们对几类纳米颗粒的肺损伤/摄取/运输的初步数据,(由聚苯乙烯、二氧化硅和金属(氧化物)组成),具有明确的物理化学特性,以及最近关于吸入超细空气污染物颗粒对健康影响的报告,我们假设纳米颗粒和肺泡上皮细胞之间的相互作用i)可破坏正常肺泡上皮细胞稳态并诱导细胞特性和肺泡上皮屏障功能的变化,ii)提供纳米颗粒通过经上皮易位途径进入体循环的主要入口,和iii)高度依赖于纳米颗粒的物理化学性质。在体外模型中使用定义的聚苯乙烯、二氧化硅和金属(氧化物)纳米颗粒(包括我们建立的大鼠或人肺泡上皮细胞的原代培养单层)和大鼠肺的体内实验,我们将通过研究以下四个主要目的来测试这些假设:1)纳米颗粒对肺泡上皮的主动和被动屏障性质的影响; 2)纳米颗粒在肺泡上皮细胞中的内化、转归和作用; 3)纳米颗粒在体外跨肺泡上皮的运输;和4)纳米颗粒在体内大鼠肺中的内化和运输,体内与体外将损伤与远端呼吸道上皮/摄取进入远端呼吸道上皮/穿过远端呼吸道上皮运输相关联。此外,我们将利用在可渗透过滤器和巨大单层囊泡上重建的人工脂质双层的简化模型来确定被动机制(例如,扩散)和/或破坏纳米颗粒进入/离开肺泡上皮细胞的脂质双层。本文提出的研究结果将提供对细胞毒性和具有确定的理化性质的纳米颗粒内化/运输进入/穿过肺泡上皮的机制的见解。我们的主要目标是获得有关纳米颗粒与肺泡上皮相互作用的新信息,以帮助了解吸入的制造纳米颗粒和环境空气污染物超细颗粒对肺部的影响,为管理由此产生的有害影响指明方向,并改进定义纳米颗粒的设计,以实现更安全、更有效的生物医学应用(例如,肺部药物/基因递送)。 公共卫生相关性:吸入超细环境污染物颗粒(<100 nm)可能与心血管和肺部不良影响有关,导致易感人群发病率和死亡率增加。这些纳米颗粒损伤和/或转运进入/穿过肺的远端气隙内衬的肺泡上皮的机制还没有很好地理解,尽管已知它们可以影响肺泡上皮的屏障性质并被肺泡上皮细胞内化/易位穿过肺泡上皮细胞。我们将使用三类定义的纳米颗粒(由聚苯乙烯、二氧化硅或金属(氧化物)组成)来确定与肺泡屏障的体外和体内模型的相互作用,以帮助防止吸入纳米颗粒的损伤并设计用于生物应用的纳米颗粒(例如,药物/基因递送)。
英文摘要
DESCRIPTION (provided by applicant): Inhalation of ultrafine (nano)particles has been associated with adverse cardiovascular, pulmonary and hematologic effects, localization of particles in blood vessels and end organs, and increased morbidity and mortality in susceptible populations. Since the particles are inhaled, their most likely route of entry into the systemic circulation is across the alveolar epithelium of the lung. Although utilization of nanoparticles due to expansion of the science and application of nanotechnology is expected to markedly increase, the mechanisms by which nanoparticles injure and/or are transported into/across alveolar epithelium are not well known. Based on our preliminary data on lung injury/uptake/trafficking of several classes of nanoparticles (composed of polystyrene, silica and metal (oxides)) with defined physicochemical characteristics and recent reports on health effects of inhaled ultrafine air pollutant particulates, we hypothesize that interactions between nanoparticles and alveolar epithelial cells i) can disrupt normal alveolar epithelial cell homeostasis and induce changes in cellular properties and alveolar epithelial barrier function, ii) provide the primary portal of entry for nanoparticles into the systemic circulation via transepithelial translocation pathways, and iii) are highly dependent on physicochemical properties of the nanoparticles. Utilizing defined polystyrene, silica and metal (oxide) nanoparticles in vitro models (including our well-established primary cultured monolayers of rat or human alveolar epithelial cells) and rat lungs in vivo, we will test these hypotheses by investigating the following four major aims: 1) nanoparticle effects on active and passive barrier properties of alveolar epithelium; 2) internalization, fate and effects of nanoparticles in alveolar epithelial cells; 3) trafficking of nanoparticles across alveolar epithelium in vitro; and 4) nanoparticle internalization and trafficking in rat lungs in vivo, correlating injury to/uptake into/trafficking across distal respiratory epithelium in vivo vs. in vitro. In addition, we will utilize simplified models of artificial lipid bilayers reconstituted on permeable filters and giant unilamellar vesicles to determine the role(s) of passive mechanisms (e.g., diffusion) and/or disruption of lipid bilayers in nanoparticle entry into/exit from alveolar epithelial cells. Findings from the investigations proposed herein will provide insights into cytotoxicity and mechanisms of internalization/trafficking of nanoparticles with defined physicochemical properties into/across the lung alveolar epithelium. Our major objective is to obtain new information on nanoparticle interactions with alveolar epithelium in order to help understand effects on the lung of inhaled manufactured nanoparticles and environmental air pollutant ultrafine particulates, point directions for management of resultant deleterious effects, and lead to improved design of defined nanoparticles for safer and more efficient biomedical applications (e.g., pulmonary drug/gene delivery). PUBLIC HEALTH RELEVANCE: Inhalation of ultrafine ambient pollutant particles (<100 nm) may be associated with adverse cardiovascular and pulmonary effects, resulting in increased morbidity and mortality in susceptible populations. The mechanisms by which these nanoparticles injure and/or are transported into/across alveolar epithelium lining distal airspaces of the lung are not well understood, although it is known that they can affect barrier properties of alveolar epithelium and be internalized by/translocated across alveolar epithelial cells. We will use three classes of defined nanoparticles (comprised of polystyrene, silica or metal (oxide)) to determine interactions with both in vitro and in vivo models of the alveolar barrier in order to help prevent injury from inhaled nanoparticles and design nanoparticles for biological applications (e.g., drug/gene delivery).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
  • 批准号:
    8870404
  • 项目类别:
  • 资助金额:
    $44.18万
  • 财政年份:
    2011
  • 负责人:
    EDWARD DAVID CRANDALL
  • 依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
  • 批准号:
    8324915
  • 项目类别:
  • 资助金额:
    $102.9万
  • 财政年份:
    2011
  • 负责人:
    EDWARD DAVID CRANDALL
  • 依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
  • 批准号:
    8499408
  • 项目类别:
  • 资助金额:
    $113.85万
  • 财政年份:
    2011
  • 负责人:
    EDWARD DAVID CRANDALL
  • 依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
  • 批准号:
    8138094
  • 项目类别:
  • 资助金额:
    $105.17万
  • 财政年份:
    2011
  • 负责人:
    EDWARD DAVID CRANDALL
  • 依托单位:
海外基金